MYHIBBIN Drug Patent Profile

Which patents cover Myhibbin, and what generic alternatives are available?

Myhibbin is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug.

This drug has four patent family members in three countries.

The generic ingredient in MYHIBBIN is mycophenolate mofetil. There are thirty-eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the mycophenolate mofetil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Myhibbin

A generic version of MYHIBBIN was approved as mycophenolate mofetil by HIKMA on July 29^th, 2008.

Summary for MYHIBBIN

International Patents:	4
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in MYHIBBIN?	MYHIBBIN excipients list
DailyMed Link:	MYHIBBIN at DailyMed

Pharmacology for MYHIBBIN

Drug Class

Antimetabolite Immunosuppressant

US Patents and Regulatory Information for MYHIBBIN

MYHIBBIN is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	MYHIBBIN	mycophenolate mofetil	SUSPENSION;ORAL	216482-001	May 1, 2024		RX	Yes	Yes			Y
Azurity	MYHIBBIN	mycophenolate mofetil	SUSPENSION;ORAL	216482-001	May 1, 2024		RX	Yes	Yes			Y
Azurity	MYHIBBIN	mycophenolate mofetil	SUSPENSION;ORAL	216482-001	May 1, 2024		RX	Yes	Yes			Y

International Patents for MYHIBBIN

See the table below for patents covering MYHIBBIN around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2020039263
European Patent Office	3836898	SUSPENSION PHARMACEUTIQUE POUR FORME GALÉNIQUE ORALE (PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE)
United Kingdom	2591396	Pharmaceutical suspension for oral dosage

Supplementary Protection Certificates for MYHIBBIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0281713	SPC/GB96/026	United Kingdom		PRODUCT NAME: MYCOPHENOLATE MOFETIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 53337 19951103; CH 53338 19951103; UK EU/1/96/005/001 19960214; UK EU/96/005/002 19960214
0281713	96C0031	Belgium		PRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103

MYHIBBIN Market Analysis and Financial Projection

Last updated: April 25, 2026

MYHIBBIN (mycophenolate mofetil)

What is MYHIBBIN and where is it sold?

MYHIBBIN is a branded presentation of mycophenolate mofetil (MMF) indicated to prevent organ rejection in transplant settings. Product availability and pricing vary by geography and payer structure. Market dynamics for MYHIBBIN track closely to the broader MMF class because MMF is a long-running, widely used immunosuppressant and is exposed to generic competition, formulary access constraints, and patent-expiration timelines for branded presentations.

Commercial premise: The branded opportunity for MYHIBBIN is typically constrained by (1) MMF’s long market history, (2) generic MMF erosion, and (3) payer policies tied to cost per treated member per month (CPPM), which tends to compress branded net pricing over time.

How does the MMF drug class shape MYHIBBIN demand?

MYHIBBIN demand is driven by transplant procedure volume and maintenance immunosuppression adherence. MMF is a cornerstone agent in many post-transplant regimens, so the demand base is relatively steady, but branded share usually degrades as generics and biosimilar-like substitution mechanisms (for small molecules: generics) expand.

Key demand drivers (MMF-level):

• Transplant incidence (kidney, heart, liver, and other solid organ categories depending on label scope by country).
• Regimen inertia: clinicians often maintain established immunosuppression schedules unless safety signals, intolerance, or cost pressures arise.
• Therapeutic switching cost: dose conversion, monitoring, and tolerability considerations can slow substitution, but do not prevent it once payer mandates and generic penetration reach critical mass.

Key demand headwinds (branded presentation-level):

• Generic substitution: PPIs, formularies, and pharmacy benefit managers tend to favor the lowest net-cost MMF product where coverage is not restricted to branded drug.
• Tendering and hospital procurement: in many markets, public hospital procurement pushes pricing down after generic entry.
• Safety-driven utilization shifts: MMF adverse effects (gastrointestinal intolerance, hematologic effects) can shift some patients to alternative immunosuppressants, but this is usually measured at class level rather than brand-specific.

What market dynamics are most likely to govern MYHIBBIN revenue trajectory?

MYHIBBIN’s financial trajectory is primarily a function of net price compression and share movement rather than new indication-driven demand spikes, since MMF is mature and most incremental growth comes from underlying transplant growth rather than label expansion.

1) Branded net pricing vs generic benchmark

For a mature molecule, branded net sales typically decline when any of the following take hold:

• Broad formulary listing of lower-cost MMF generics.
• Contracting strategies that peg branded pricing to generic net pricing.
• Hospital tender outcomes that replace branded stock with generic supply.

Expected pattern: Over time, branded products trend toward a lower share of total MMF scripts, with remaining volume concentrated where clinicians or payer policies restrict interchangeability or where brand-specific access programs persist.

2) Share protection through specialty channel access

If MYHIBBIN maintains share, it is usually because at least one of these conditions holds:

• Restricted interchangeability in certain payer contracts.
• Softer substitution where physicians use the same product for consistency.
• Patient-specific tolerability history with the branded product.

Expected pattern: Share protection is rarely permanent. It typically slows erosion rather than preventing it.

3) Forecast sensitivity to transplant volumes

Solid organ transplant volumes are the cleanest demand lever. Growth in the eligible population, improved care pathways, and aging demographics can increase procedure counts. But transplant policy changes, system-level budget pressure, and transplant center throughput can also shift annual volumes.

Expected pattern: If transplant volumes grow modestly, class-level MMF demand follows; branded sales still depend on net price and share.

Financial trajectory: what to expect for MYHIBBIN

A complete financial trajectory (exact historical revenue, gross-to-net evolution, and forward guidance) requires company filings and market-level dataset coverage. This cannot be produced accurately from the information provided. What can be stated precisely is the mechanical revenue logic for MYHIBBIN as a branded MMF presentation in a mature molecule:

Revenue = (Total treated patients) × (MMF dose intensity) × (brand share) × (net price)

For mature branded MMF, the main moving variables are:

• Brand share: downtrend after generic entry and payer widening.
• Net price: downtrend due to rebates, tender pricing, and formulary pressure.
• Treated patients and dose intensity: relatively stable at class level, linked to transplant numbers and regimen norms.

Likely trajectory shape

• Initial phase post-launch/access: higher net pricing and tighter competition.
• Transition phase: generic availability triggers price pressure and slower-than-class decline if restricted access persists.
• Later phase: branded share compresses toward a residual level; net price approaches generic benchmark levels.

How do payers, hospitals, and procurement typically translate into net sales?

For a transplanted immunosuppressant, net sales behavior is dominated by:

• Hospital procurement cycles (tender calendar impacts quarterly timing).
• National reimbursement formularies (coverage rules determine switching rates).
• Managed entry agreements (volume discounts, rebates, or patient assistance programs, where applicable).

Operational translation into numbers (directional):

• When generics are preferred on formularies, MYHIBBIN net revenue per script falls and scripts migrate.
• When hospital tender cycles conclude, sales often show step-change declines rather than gradual erosion.

Competitive landscape: what matters vs other MMF products

For MYHIBBIN, the relevant competitive set is:

• Generic MMF brands (multi-source competition).
• Other immunosuppressants in regimen design (though these typically compete by substitution when intolerance occurs).

Most important competitor type for revenue erosion: multi-source generic MMF. Secondary competitor type: regimen alternatives, which affect class total demand less consistently than generics do.

Investment and R&D implications (commercial, not preclinical)

MYHIBBIN’s financial profile is usually treated as a cash-flow product rather than a growth engine in mature-market MMF. The main strategic questions for investors and planners are:

• Whether the product retains differentiated access pathways that delay generic displacement.
• Whether manufacturer contracting can maintain net price despite competitive benchmarks.
• Whether any new formulations or optimized dosing create procurement stickiness.

For MMF brands, “pipeline-like” growth is limited unless there is a meaningful formulation differentiation with payer-relevant outcomes or a new population in label that changes treatable volume.

Key market signals to track for MYHIBBIN

Because MYHIBBIN competes in a mature small-molecule market, the most decision-useful indicators are commercial, not clinical:

1. Formulary and interchange status in major payer grids (coverage restrictions and therapeutic substitution rules).
2. Tender outcomes in large hospital systems.
3. Net price trends versus generic benchmarks by geography.
4. Script share trends for MMF overall and brand-specific decline rates.
5. Transplant volume trends from health authority or transplant registries.

Key Takeaways

• MYHIBBIN’s market dynamics are dominated by MMF class maturity and generic erosion, not by trial-driven uptake.
• Revenue trajectory is primarily controlled by brand share decline and net price compression through formulary and procurement mechanisms.
• The demand base is relatively stable because MMF is a common maintenance immunosuppressant, but branded presentations typically trend toward residual share after widespread generic inclusion.
• Accurate financial trajectory requires revenue and net pricing data from filings or market datasets; without those inputs, only the revenue mechanics and expected pattern can be stated.

FAQs

1. Is MYHIBBIN a new chemical entity?
   No. MYHIBBIN is a branded presentation of mycophenolate mofetil (MMF), a mature immunosuppressant used in transplant immunosuppression.

2. What drives MYHIBBIN demand most?
   Solid organ transplant volumes and long-term maintenance immunosuppression adherence.

3. What is the biggest financial risk to MYHIBBIN?
   Generic MMF substitution triggered by formulary and hospital procurement shifts that reduce net price and brand scripts.

4. Does clinical differentiation change the commercial outlook?
   Only if it translates into payer-relevant differentiation (coverage restrictions, reduced monitoring burden, or procurement stickiness). In mature MMF markets, most differences do not prevent generic erosion.

5. What commercial indicators best predict MYHIBBIN sales direction?
   Formulary listing status, tender outcomes, net price versus generic benchmarks, and brand-specific script share trends.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Approval Reports and labels for mycophenolate mofetil (MMF) products.
[2] European Medicines Agency (EMA). Product information and assessment materials for mycophenolate mofetil in transplant indications.